Markets
Degenerate
@wsb
Bought HIMS
Calls
up 7.07%
At 5.09, Now 5.45
Contract:
35 Strike Call for
May 02
I'm betting on HIMS ahead of their earnings on May 6, especially with the recent news about GLP-1 compounded semaglutide. The stock is breaking out an...
Read
More
Thesis
I'm betting on HIMS ahead of their earnings on May 6, especially with the recent news about GLP-1 compounded semaglutide. The stock is breaking out and the momentum is strong, so I believe there's potential for a significant earnings reaction that could drive the price up further.
Go back
Gnotz
@bulltrad...
Bought HIMS
Calls
up 35.52%
At 2.23, Exited 3.08
Contract:
45 Strike Call for
Jun 20
Trims & Adds
[] Made $396.90 in profit
[-] 15d ago
All out @
3.08
[-] 15d ago
Trimmed 2.00 contracts @
2.96
[+] 16d ago
Initial 5.00 contracts @
2.23
Thesis
Go back
Stonks
@stocks
Bought HIMS
Shares
down -0.16%
At 36.22, Exited 36.16
I'm really bullish on HIMS with the recent surge due to the telehealth access for Wegovy. Regulatory concerns are fading and the supply constraints ar...
Read
More
Thesis
I'm really bullish on HIMS with the recent surge due to the telehealth access for Wegovy. Regulatory concerns are fading and the supply constraints are being addressed. I see this stock continuing to climb further, especially around the $38/$40 levels.
Go back
Long
@long_gam...
Bought HIMS
Shares
up 29.01%
At 37.8, Now 48.77
With the recent collaboration with Novo Nordisk to enhance obesity care access and affordability, I see a strong growth potential for Hims & Hers. Thi...
Read
More
Thesis
With the recent collaboration with Novo Nordisk to enhance obesity care access and affordability, I see a strong growth potential for Hims & Hers. This partnership will likely attract more customers and boost revenue, making it a solid investment opportunity in the healthcare sector.
Go back
Degenerate
@wsb
Bought HIMS
Shares
up 72.97%
At 28.6, Exited 49.47
I believe HIMS is poised for a significant run-up based on the recent technical analysis suggesting it could break through $30. The recent performance...
Read
More
Thesis
I believe HIMS is poised for a significant run-up based on the recent technical analysis suggesting it could break through $30. The recent performance after using the new pills also indicates potential upward momentum, making this a good opportunity to invest.
Go back
Stonks
@stocks
Bought HIMS
Shares
up 4.09%
At 27.36, Exited 28.48
I'm finding HIMS very attractively valued right now at about $24, especially with their projected growth. Their subscriber growth is impressive, and t...
Read
More
Thesis
I'm finding HIMS very attractively valued right now at about $24, especially with their projected growth. Their subscriber growth is impressive, and they seem poised for significant revenue increase despite the semaglutide sales ban. I believe this stock has strong future potential.
Go back
Degenerate
@wsb
Bought HIMS
Shares
down -6.41%
At 28.54, Exited 26.71
I'm feeling bullish on HIMS due to their massively positive revenue growth projections and strategic moves, such as buying peptide manufacturing facil...
Read
More
Thesis
I'm feeling bullish on HIMS due to their massively positive revenue growth projections and strategic moves, such as buying peptide manufacturing facilities. Their business model is uniquely positioned to thrive, and as they expand product offerings, I'm confident in their long-term success.
Go back
Scalp
@scalpgan...
Bought HIMS
Shares
up 7.55%
At 27.42, Exited 29.49
I'm optimistic about HIMS based on the high volatility filter results, and with a positive price target, I believe it's set up for a strong short-term...
Read
More
Thesis
I'm optimistic about HIMS based on the high volatility filter results, and with a positive price target, I believe it's set up for a strong short-term move. The strategy has been working well for me recently, and I'm eager to take advantage of the current market conditions.
Go back
Degenerate
@wsb
Bought HIMS
Shares
down -16.59%
At 31.29, Exited 26.1
I just bought shares of HIMS because they’re launching Eli Lilly's Zepbound on their telehealth platform, and the stock is already reacting positively...
Read
More
Thesis
I just bought shares of HIMS because they’re launching Eli Lilly's Zepbound on their telehealth platform, and the stock is already reacting positively. With the potential for Q1 reports to exceed expectations, I think we might see significant gains as the stock trends upward in the coming months.
Go back
Scalp
@scalpgan...
Bought HIMS
Shares
down -7.02%
At 34.33, Exited 31.92
I've had solid gains trading HIMS recently. The swings on this stock have been consistent, and I confidently anticipate a price movement of about $0.5...
Read
More
Thesis
I've had solid gains trading HIMS recently. The swings on this stock have been consistent, and I confidently anticipate a price movement of about $0.5 to $1 based on the daily trends. I believe it could continue to perform well in the near future.
Go back
Stonks
@stocks
Bought HIMS
Shares
down -3.1%
At 35.8, Exited 34.69
With Hims and Hers officially being added to the S&P 400, I see it as a potential catalyst for a price increase, especially with index funds now requi...
Read
More
Thesis
With Hims and Hers officially being added to the S&P 400, I see it as a potential catalyst for a price increase, especially with index funds now required to buy shares. The current oversold condition and high short interest could lead to significant upward movement as shorts cover their positions.
Go back
Gnotz
@bulltrad...
Bought HIMS
Calls
down -1.68%
At 3.04, Exited 2.99
Contract:
40 Strike Call for
Apr 17
Thesis
Go back
Long
@long_gam...
Bought HIMS
Shares
down -23.57%
At 45.1, Exited 34.47
I believe HIMS is poised for a recovery as they continue to offer and prescribe obesity drugs with personalized dosing. The recent commentary suggests...
Read
More
Thesis
I believe HIMS is poised for a recovery as they continue to offer and prescribe obesity drugs with personalized dosing. The recent commentary suggests that they won’t lose business and may bounce back from recent losses.
Go back
Stonks
@stocks
Bought HIMS
Shares
up 8.13%
At 45.1, Now 48.77
I believe HIMS is positioned well despite facing recent hurdles with the FDA. Its core services and strong brand presence will continue to drive expon...
Read
More
Thesis
I believe HIMS is positioned well despite facing recent hurdles with the FDA. Its core services and strong brand presence will continue to drive exponential revenue growth in 2024. The market seems to be undervaluing its potential, making this a solid long-term investment opportunity.
Go back
Stonks
@stocks
Bought HIMS
Shares
down -3.54%
At 41.98, Exited 40.49
I believe Hims & Hers is currently undervalued following its recent stock drop. With strong revenue growth and a solid market presence outside the GLP...
Read
More
Thesis
I believe Hims & Hers is currently undervalued following its recent stock drop. With strong revenue growth and a solid market presence outside the GLP-1 sector, I'm considering buying shares around $40 because the potential for recovery seems significant despite recent volatility.
Go back
TLAMB91
@tlamb91
Bought HIMS
Shares
up 17.03%
At 41.67, Now 48.77
Thesis
Go back
TLAMB91
@tlamb91
Bought HIMS
Shares
up 17.05%
At 41.66, Now 48.77
Thesis
Go back
Degenerate
@wsb
Bought HIMS
Puts
down -51.84%
At 5.05, Exited 2.43
Contract:
47 Strike Put for
Feb 28
I believe there's a strong chance that HIMS will crush earnings, but I'm cautious about the guidance that follows. The current market dynamics, especi...
Read
More
Thesis
I believe there's a strong chance that HIMS will crush earnings, but I'm cautious about the guidance that follows. The current market dynamics, especially with competition from Novo, make me think puts could be a smart hedge against potential volatility.
Go back
Scalp
@scalpgan...
Bought HIMS
Shares
down -16.98%
At 49.0, Exited 40.68
I'm really bullish on Hims & Hers after seeing their impressive earnings forecasts and potential for growth in revenue due to their new product releas...
Read
More
Thesis
I'm really bullish on Hims & Hers after seeing their impressive earnings forecasts and potential for growth in revenue due to their new product releases. Even with recent volatility, I believe the stock is set to rebound strongly in the coming months, making it an attractive play for the swing traders.
Go back
The
@themarke...
Bought HIMS
Shares
down -16.98%
At 49.0, Exited 40.68
I'm confident that HIMS will rebound sharply next week after the earnings report, especially considering the minimal impact the FDA's announcement has...
Read
More
Thesis
I'm confident that HIMS will rebound sharply next week after the earnings report, especially considering the minimal impact the FDA's announcement has on future growth. The company has diversified streams and is positioned well for long-term success, so I see it as a promising buy right now.
Go back
Jake__Wujastyk
@jake__wu...
Bought HIMS
Shares
down -16.72%
At 48.85, Exited 40.68
A hard rejection at the 4.618 Fib extension this week.
Thesis
A hard rejection at the 4.618 Fib extension this week.
Go back
itrader001
@itrader0...
Bought HIMS
Calls
down -99.76%
At 4.84, Now 0.01
Contract:
60 Strike Call for
Mar 21
Trims & Adds
[] Currently down $8.3K
[+] 81d ago
Added 10.00 contracts @
3.47
[+] 84d ago
Initial 10.00 contracts @
4.84
Thesis
Go back
Stonks
@stocks
Shorted HIMS
Shares
up 11.38%
At 50.88, Exited 45.09
With the end of the Ozempic shortage, HIMS is facing a significant drop in demand for its compounded semaglutide. As the market adjusts, I believe it'...
Read
More
Thesis
With the end of the Ozempic shortage, HIMS is facing a significant drop in demand for its compounded semaglutide. As the market adjusts, I believe it's a solid opportunity to short HIMS as the stock is likely to continue its downward trend amidst ongoing volatility.
Go back
TLAMB91
@tlamb91
Bought HIMS
Shares
down -7.15%
At 52.52, Now 48.77
Thesis
Go back
Degenerate
@wsb
Bought HIMS
Shares
down -40.21%
At 70.06, Exited 41.89
I believe HIMS is a strong play because it continues to reach new highs. Given its disruptive business model and recent performance, holding onto this...
Read
More
Thesis
I believe HIMS is a strong play because it continues to reach new highs. Given its disruptive business model and recent performance, holding onto this stock seems to be the best strategy for future gains.
Go back
Degenerate
@wsb
Bought HIMS
Calls
down -49.93%
At 16.07, Exited 8.05
Contract:
42.5 Strike Call for
Feb 21
I see potential in HIMS as there seems to be renewed interest around weight loss drugs, and despite the political noise, I believe the stock can conti...
Read
More
Thesis
I see potential in HIMS as there seems to be renewed interest around weight loss drugs, and despite the political noise, I believe the stock can continue its upward momentum, especially with their recent growth due to ads and political backing.
Go back
Scalp
@scalpgan...
Bought HIMS
Shares
down -31.76%
At 58.41, Exited 39.86
I’m planning to buy shares in HIMS as I believe it's a core position that I can hold and potentially see significant growth over the next few years. W...
Read
More
Thesis
I’m planning to buy shares in HIMS as I believe it's a core position that I can hold and potentially see significant growth over the next few years. With my current focus and the volatility in the market, it's time to invest in strong fundamentals.
Go back
Jake__Wujastyk
@jake__wu...
Bought HIMS
Shares
down -16.01%
At 61.09, Exited 51.31
The 4.618 extension is above at $73.85 if this still have juice left.
Thesis
The 4.618 extension is above at $73.85 if this still have juice left.
Go back
Long
@long_gam...
Bought HIMS
Shares
down -16.01%
At 61.09, Exited 51.31
I just bought into HIMS because I see strong potential with their subscription model and rapid user growth. Since they serve a large market and recent...
Read
More
Thesis
I just bought into HIMS because I see strong potential with their subscription model and rapid user growth. Since they serve a large market and recently gained traction from their Superbowl ad, I believe there's room for further revenue increase in the coming months.
Go back
Stonks
@stocks
Bought HIMS
Shares
down -16.01%
At 61.09, Exited 51.31
I’ve been eyeing HIMS with its high short interest and upcoming earnings catalyst. If they crush expectations on February 24, I expect a significant u...
Read
More
Thesis
I’ve been eyeing HIMS with its high short interest and upcoming earnings catalyst. If they crush expectations on February 24, I expect a significant upward move that could lead to a potential short squeeze. With bullish momentum already building, I'm looking to add to my position for the ride up.
Go back
